AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 43.8 USD -1.6% Market Closed
Market Cap: 1.2B USD

AnaptysBio Inc
Total Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

AnaptysBio Inc
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
AnaptysBio Inc
NASDAQ:ANAB
Total Liabilities
$382.5m
CAGR 3-Years
4%
CAGR 5-Years
73%
CAGR 10-Years
38%
Abbvie Inc
NYSE:ABBV
Total Liabilities
$136.5B
CAGR 3-Years
3%
CAGR 5-Years
0%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities
$37.1B
CAGR 3-Years
-4%
CAGR 5-Years
-3%
CAGR 10-Years
1%
Amgen Inc
NASDAQ:AMGN
Total Liabilities
$80.5B
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities
$7.5B
CAGR 3-Years
27%
CAGR 5-Years
19%
CAGR 10-Years
17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities
$9.2B
CAGR 3-Years
14%
CAGR 5-Years
9%
CAGR 10-Years
17%
No Stocks Found

AnaptysBio Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

ANAB Intrinsic Value
69.95 USD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is AnaptysBio Inc's Total Liabilities?
Total Liabilities
382.5m USD

Based on the financial report for Sep 30, 2025, AnaptysBio Inc's Total Liabilities amounts to 382.5m USD.

What is AnaptysBio Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
38%

Over the last year, the Total Liabilities growth was -6%. The average annual Total Liabilities growth rates for AnaptysBio Inc have been 4% over the past three years , 73% over the past five years , and 38% over the past ten years .

Back to Top